spacer
home > pmps > autumn 2003 > beating the bottleneck in contract packaging
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Beating the Bottleneck in Contract Packaging

The world of packaging today finds itself uncomfortably in the manufacturing industry spotlight. On the one side, it faces a seemingly continuous, complex and costly stream of new legislation and regulation, such as the new rules for child-proofing blister packs that come into force this autumn. On the other, it is a major target for senior management teams that are seeking, with increasing urgency, to identify and extract significant cost-efficiencies ahead of the impending 2010 deadline by which many patents will expire. Packaging is expected to provide a major source of competitive advantage, improving performance, availability and consistency by as much as 50 per cent while retaining a motivated and healthy customer base.

'Catch 22' or a 'Third Way'

Many pharmaceutical manufacturers who opt to conduct packaging operations in-house are confronted with a 'catch 22' situation. Do they invest sufficiently to create the capacity and flexibility necessary to meet high seasonable demand variability? Or do they try to manage the consequences of a disrupted distribution chain to market?


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Guy Malchi, Associate Partner of the Life Science Sector at Tefen Operations Management Consulting

Guy Malchi is Associate Partner within Tefen Europe and is responsible for the supervision and management of performance improvement projects in pharmaceutical, biotech, medical devices and related industries. Since joining Tefen, he has been instrumental in the success of many projects, particularly within his industry specialism, including Janssen, AstraZeneca, Pharmacia and Aventis. Mr Malchi holds a BSc in Industrial Engineering and is completing an Executive MBA at London Business School.

spacer
Guy Malchi
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Case Study: Getting the Client’s Trust - Oncology Program

Cmed Clinical Services

Five years ago, a biopharmaceutical company chose Cmed to conduct a phase II oncology study. Cmed’s performance of the study and the good relationship established with the Client led Cmed to be awarded a second oncology trial which a couple of years ago was followed by a third, fourth and fifth.
More info >>

 
Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement